NCT06733363
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +17 more
- Locations
-
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Clinical trial condition
Stage 0a Bladder Cancer AJCC v8
Explore clinical trials studying Stage 0a Bladder Cancer AJCC v8. Study availability and eligibility vary by location and protocol.
12 public trials
5 recruiting studies
Stage 0a Bladder Cancer AJCC v8 trial results
NCT07000084
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Fairbanks Memorial Hospital Fairbanks, Alaska, United States
- Banner MD Anderson Cancer Center Gilbert, Arizona, United States
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
NCT07302230
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, +12 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT06704191
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +16 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT06173349
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +16 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Active, not recruiting
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082
- Conditions
- Bladder Flat Urothelial Carcinoma In Situ, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Active, not recruiting
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
NCT05843448
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, +12 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Active, not recruiting
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT06350734
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +13 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Completed
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
NCT04501913
- Conditions
- Adenocarcinoma, Adnexal Diseases, Carcinoma, +213 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT04548193
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +11 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States